Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes. (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021)